Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neurodegenerative disorders. The company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, Advent France Biotechnology and Gemma Frisius Fund.
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neurodegenerative disorders. The company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, Advent France Biotechnology and Gemma Frisius Fund.
